Banc of America Downgrades Gilead Sciences (GILD) to Neutral
More News related to GILD
- Gilead Sciences Announces Notification of ANDA Filing for Truvada
- David Moenning's Daily State of the Markets: 11/12
- Notable Analyst Rating Changes 11/12: BBBY, PAG, ROK Upgraded; EGLE, FMCN, BRCM Downgraded
- Needham & Co Initiates Coverage on Gilead Sciences (GILD), Represents Core Holding
- Deloitte Unveils 2008 Technology Fast 500 Ranking
More News related to Downgrades
- Honda Develops Ecological Drive Assist System for Enhanced Real World Fuel Economy
- Islamic Finance is Helping Fill the Liquidity Gap Caused by the Global Crisis in Conventional Banking-This NEW BOOK Explains How
- FMC Technologies Acquires Interest in Roxar ASA
- NYX Interactive Goes East - Establishes a Business in Singapore
- Sandvik Reduces Production Capacity and Costs
Banc of America downgrades Gilead Sciences (Nasdaq: GILD) from Buy to Neutral and lowers their price target to $56.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Related Categories
DowngradesStocks Mentioned
-2.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
